Victor Chiu, MD
Ophthalmology · Tacoma, WANPI 1285664375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Glaukos Corporation at 50.8% of the total. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $52.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$5K
- AbbVie$1K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$667
- Rxsight Inc$483
- Sun Pharmaceutical Industries Inc.$192
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$320%
- Food & beverage$9,65299%
- Gifts$390%
- Entertainment$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 60 | $4,969 |
| AbbVie(2 entities) | 30 | $1,414 |
| Alcon | 23 | $1,037 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $667 |
| Rxsight Inc | 9 | $483 |
| Sun Pharmaceutical Industries Inc. | 11 | $192 |
| Rayner Intraocular Lenses Limited | 2 | $154 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $150 |
| Daiichi Sankyo Inc. | 4 | $147 |
| Bausch & Lomb Americas Inc. | 7 | $134 |
| Biotissue Holdings Inc. | 3 | $62 |
| Novartis | 3 | $56 |
| Staar Surgical Company | 2 | $55 |
| Carl Zeiss Meditec USA, Inc. | 1 | $51 |
| Thea Pharma Inc. | 2 | $41 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Heidelberg Engineering, Inc. | 1 | $37 |
| NEW World Medical,inc. | 1 | $34 |
| Oyster Point Pharma, Inc. | 1 | $28 |
| Akorn Operating Company LLC | 1 | $14 |
| Iridex Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject W$1,582
- IACCESS$798
- iDoseTR$593
- iStent Infinite$593
- KXL System$537
- XEN$520
- Photrexa$376
- iAccess Precision Blade$323
- iStent Trabecular Micro-Bypass Stent System$291
- iDose$287
- RXSIGHT CONTACT LENS$280
- RXSIGHT INJECTOR CARTRIDGE$280
- RXSIGHT INJECTOR HANDPIECE$280
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$280
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$280
- Tecnis IOL$239
- iStent Trabecular Micro-Bypass System Model iS3$194
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$183
- iStent infinite Trabecular Micro-Bypass System Model iS3$183
- iStent$161
How this compares
$9,778 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 54 | $50,617 |
| Prednisolone Acetate | 699 | $21,637 |
| LumiganBimatoprost | 24 | $14,998 |
| Ketorolac Tromethamine | 683 | $13,954 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 77 | $9,918 |
| Latanoprost | 758 | $7,986 |
| Travoprost | 79 | $6,861 |
| Ofloxacin | 560 | $6,358 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $5,404 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 213 | $3,040 |
| Brinzolamide | 16 | $3,015 |
| Difluprednate | 25 | $2,745 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,259 |
| Timolol Maleate | 95 | $1,252 |
| Atropine Sulfate | 40 | $1,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,414 | $71,01998 claims |
| AlconSimbrinza | $1,037 | $2,25911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Tacoma
- Andrew KopsteinTacoma$57K
- Clifton PerryTacoma$50K
- Niraj PatelTacoma$13K
- Joseph PhamTacoma$10K
- Jacob LightTacoma$10K
- Mark NelsonTacoma$7K
- Francis GeisslerTacoma$6K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.